BT44 is a selective
[1]. Viisanen H, et al. Novel RET agonist for the treatment of experimental neuropathies. Mol Pain. 2020 Jan-Dec;16:1744806920950866.
[2]. Renko JM, et al. Neuroprotective Potential of a Small Molecule RET Agonist in Cultured Dopamine Neurons and Hemiparkinsonian Rats. J Parkinsons Dis. 2021;11(3):1023-1046.
















